NKGen Biotech

NKGen Biotech Equity Growth

The Year-over-Year Equity Growth of NKGen Biotech (NKGN) as of Nov 22, 2026 is -3,855.15 %. In the previous year, Year-over-Year Equity Growth was 104.11 % — a change of -3,803.05% (lower).

Equity Growth

-3,855.15 %

YoY

-3,803.05%

Last updated:

Year-over-Year Equity Growth of NKGen Biotech is 2023 -3,855.15 % . Year-over-Year Equity Growth of NKGen Biotech was 2022 104.11 % . It decreases by -3,803.05% lower compared to the previous year.

The NKGen Biotech Equity Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity Growth
Date
Equity Growth
Jan 1, 2022
104.11 USD
Jan 1, 2023
-3,855.15 USD
The NKGen Biotech Equity Growth history
YEAREquity GrowthYoY
-3,855.15 %-3,803.05%
104.11 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Year-over-Year Equity Growth of NKGen Biotech is -3,855.15 % in 2023.

On Eulerpool you can find the complete historical development of Year-over-Year Equity Growth NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

Equity growth measures the percentage change in shareholders' equity. It reflects retained earnings, share issuances, and comprehensive income effects.

To evaluate Year-over-Year Equity Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Equity Growth.

Year-over-Year Equity Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Equity Growth's NKGen Biotech historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — NKGen Biotech

All Key Metrics — NKGen Biotech